Amgen Inc. $AMGN Shares Purchased by Brookstone Capital Management

Key Points

• Brookstone Capital Management increased its Amgen stake by 3.4% in the third quarter, adding 3,316 shares to hold 100,611 shares valued at approximately $42.4 million. Institutional investors collectively own 76.5% of Amgen.
• Amgen reported quarterly EPS of $6.29 and revenue of $10.05 billion, exceeding analyst expectations, while revenue grew 9.5% year over year. The company also pays an annualized dividend of $10.08 per share, yielding about 2.3%.
• AMGN recently traded near its 52-week high at $447.28, although analyst sentiment remains mixed: the consensus rating is Hold with an average price target of $388.64.

Brookstone Capital Management increased its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,611 shares of the medical research company's stock after acquiring an additional 3,316 shares during the period. Brookstone Capital Management's holdings in Amgen were worth $42,409,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. MW Advisory LLC bought a new stake in shares of Amgen in the 2nd quarter worth approximately $1,054,000. Baird Financial Group Inc. boosted its holdings in Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company's stock worth $123,057,000 after buying an additional 5,496 shares in the last quarter. Integrated Advisors Network LLC boosted its holdings in Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock worth $6,664,000 after buying an additional 6,356 shares in the last quarter. KBC Group NV boosted its holdings in Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company's stock worth $138,574,000 after buying an additional 130,497 shares in the last quarter. Finally, Nilsine Partners LLC acquired a new position in Amgen in the second quarter worth approximately $3,329,000. 76.50% of the stock is currently owned by institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 over the last 90 days. Corporate insiders own 0.85% of the company's stock.

Amgen Trading Up 2.0%

NASDAQ AMGN opened at $447.28 on Friday. The firm's 50 day moving average price is $417.22 and its two-hundred day moving average price is $377.39. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $450.98. The stock has a market cap of $241.81 billion, a price-to-earnings ratio of 27.80, a PEG ratio of 3.21 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company's revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts anticipate that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Guggenheim dropped their price target on Amgen from $388.00 to $378.00 and set a "neutral" rating on the stock in a report on Tuesday, October 13th. TD Cowen lifted their target price on Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Citigroup lifted their target price on Amgen from $345.00 to $405.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Weiss Ratings raised Amgen from a "buy (b)" rating to a "buy (b+)" rating in a report on Thursday, October 8th. Finally, Sanford C. Bernstein increased their price target on Amgen from $335.00 to $345.00 and gave the company a "market perform" rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $388.64.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Piper Sandler maintained a Buy rating and set a $457 price target, leaving additional upside from the stock’s latest 52-week high. Piper Sandler Remains a Buy on Amgen
• Positive Sentiment: Amgen reached a new 52-week high at $447.28, roughly 55% above its October lows, highlighting strong investor momentum and demand for the stock. Amgen Reaches a New 52-Week High
• Positive Sentiment: Amgen and AstraZeneca reported Phase III Tezspire data in eosinophilic esophagitis, a potential expansion opportunity for the drug and a catalyst for the companies’ respiratory-immunology portfolios. Amgen and AstraZeneca Report Phase III Tezspire Data
• Positive Sentiment: Recent fundamentals remain supportive: Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Its diversified oncology, rare-disease, and inflammation portfolio also provides a steadier cash-flow profile than some high-growth biotech peers.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.